鸟苷酸环化酶C受体治疗便秘型肠易激综合征的现状及研究进展  

The application status and research progress of guanylate cyclase C receptor agonists in constipation-predominant irritable bowel syndrome

作　　者：慕之勇 王文生 魏艳玲 陈东风 MU Zhiyong;WANG Wensheng;WEI Yanling;CHEN Dongfeng(Department of Gastroenterology,Daping Hospital,Army Medical University,Chongqing 400042,China)

机构地区：[1]陆军军医大学大坪医院消化内科,重庆400042

出　　处：《胃肠病学和肝病学杂志》2021年第5期593-597,共5页Chinese Journal of Gastroenterology and Hepatology

基　　金：陆军军医大学2019年军事医学前沿创新能力培养计划(2019CXJSB008)。

摘　　要：便秘型肠易激综合征(IBS-C)是一种由多因素导致的以腹痛、便秘为突出表现的常见疾病。IBS-C的治疗药物主要包括纤维素类、泄剂、解痉剂、促胃肠动力药、心身类药等五类,一部分患者长期使用这些药物疗效不理想,因此需要新型药物用于临床治疗。鸟苷酸环化酶C受体(GCCA)是一种新型促分泌药,主要作用于肠道黏膜上皮细胞,促进肠腔液体分泌,增加肠道蠕动及调节肠道内脏感觉,在慢性便秘及IBS-C治疗上显示出较好的临床疗效。本文针对GCCA治疗IBS-C的现状及研究进展作一概述,为临床医师提供参考。Constipation-predominant irritable bowel syndrome(IBS-C)is a common disease characterized by abdominal pain and constipation due to multiple factors.Therapeutic approaches are mainly divided into five categories,including fiber,laxatives,antispasmodics,prokinetic,and psychosomatic.However,some patients do not respond well to long-term use of these drugs,so new drugs are urgently needed for clinical treatment.Guanylate cyclase C receptor agonist(GCCA)is a new kind of secretagogue,acting on intestinal mucosal epithelial cells,promoting intestinal fluid secretion,increasing intestinal motility and regulating intestinal visceral sensation.Futhermore,it shows better clinical efficacy in the treatment of chronic constipation and IBS-C.The article reviewed the status and research progress of GCCA in the clinical application of IBS-C,providing a reference for clinicians.

关 键 词：便秘型肠易激综合征 鸟苷酸环化酶C受体 治疗 进展 

分 类 号：R574[医药卫生—消化系统]